	US 11,746,145 B2
	Tau-binding antibodies
Kerry Louise Tyson, Slough (GB); Terence Seward Baker, Slough (GB); Georges Mairet-Coello, Brussels (BE); Patrick Downey, Brussels (BE); Jean-Philippe Courade, Brussels (BE); and David Edward Ormonde Knight, Slough (GB)
Assigned to UCB BIOPHARMA SRL, Brussels (BE)
Filed by UCB BIOPHARMA SRL, Brussels (BE)
Filed on Dec. 29, 2020, as Appl. No. 17/136,440.
Application 17/136,440 is a continuation of application No. 16/458,217, filed on Jul. 1, 2019, granted, now 10,906,966.
Application 16/458,217 is a continuation of application No. 15/742,070, granted, now 10,344,081, previously published as PCT/EP2016/065809, filed on Jul. 5, 2016.
Claims priority of application No. 15175519 (EP), filed on Jul. 6, 2015.
Prior Publication US 2021/0139574 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 14/47 (2006.01); A61P 25/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); C07K 14/4711 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2821 (2013.01)]

18 Claims

1. An isolated monoclonal Tau-binding antibody or binding fragment thereof conjugated to one or more effector molecule or detectable label, wherein said Tau-binding antibody or binding fragment thereof comprises:

a light chain variable region comprising SEQ ID NO: 1 (CDR1), SEQ ID NO: 2 (CDR2) and SEQ ID NO: 3 (CDR3); and

a heavy chain variable region comprising SEQ ID NO: 4 (CDR1), SEQ ID NO: 5 (CDR2) and SEQ ID NO: 6 (CDR3).